Time to Butt Out. Adil Virani, BSc (Pharm), Pharm D, FCSHP

Similar documents
1. Describe the benefits of smoking cessation. 2. List the withdrawal symptoms of quitting smoking. Cessation

SMOKING CESSATION WORKSHOP. Dr Mark Palayew December

IMPORTANT POINTS ABOUT MEDICATIONS

Helping People Quit Tobacco

SMOKING CESSATION IS HARD

Background. Abstinence rates associated with varenicline

Smoking cessation therapy

Tobacco Dependence Screening and Treatment in Behavioral Health Settings. Prescribing

Cessation Medicine Reference Guide Table of Contents

SMOKING CESSATION. Recommendations 5As Approach to Smoking Cessation. Stages of Change Assisting the Smoker. Contributor Dr. Saifuz Sulami.

Pharmacotherapy for Treating Tobacco Dependence

Smoking and Nicotine Replacement Therapy (NRT) Lec:5

Smoke-free Hospitals. Linda A. Thomas, MS University of Michigan Health System Tobacco Consultation Service

Smoking Cessation: Treating Tobacco Dependence

5. Offer pharmacotherapy to all smokers who are attempting to quit, unless contraindicated.

Brief Counselling for Tobacco Use Cessation

SMART STEPS towards a tobacco-free life

Nicotine Replacement Therapy, Zyban and Champix. Name of presentation

NYSMPEP Smoking Cessation Guidance: Key Message 3

Keywords: tobacco, cigarette smoke, nicotine, dopamine, smoking cessation, acethylcholine, varenicline (champix )

Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services

Best Practice for Smoking Cessation: Pharmacotherapy. Emma Dean Acting Population Health and Health Promotion Coordinator Lead Pharmacist- Smokefree

Effective Treatments for Tobacco Dependence

Outpatient Tobacco Addiction Treatment Pathway Additional Notes

My Mask. I keep it all inside. Because I d rather. The pain destroy me. Than everyone else. Anon.

Pharmacologic Therapy for Tobacco Use & Dependence

Disclaimers. Smoking and Smoking Cessation. Worldwide. Objectives. Statistics at Home. Smoking Epidemic 16/10/2017

Medication Management to Aid in Smoking Cessation. Rachel Constant, Pharm.D. Baptist Health Corbin Pharmacy Resident 3/22/2019

TREATMENT OF NICOTINE DEPENDENCE

Pharmacotherapy Summary for the Treatment of Nicotine Withdrawal and Nicotine Dependence 1

4/2/2015. Inpatient Smoking Cessation. Smoking Cessation Documentation Patient's Stage of Behavior Change

TREATMENT INTERVENTIONS

After the Last Cigarette

Update on SMOKING CESSATION. Supporting the PHO Performance Programme. 38 BPJ Issue 33

PHARMACOTHERAPY OF SMOKING CESSATION

HIV and Aging. Making Tobacco Cessation a Priority in HIV/AIDS Services. Objectives. Tobacco Use Among PLWHA

Breaking the Chains of Nicotine Dependence - A Breakthrough Approach

Title: Varenicline for Smoking Cessation. Date: June 4, Context and policy issues:

AIDS for CESSATION PHARMACOTHERAPY. METHODS for QUITTING. NONPHARMACOLOGIC METHODS (cont d) NONPHARMACOLOGIC METHODS

An Evolving Perspective on Smoking Cessation Therapies

Prescribing guidance in. Smoking Cessation March 2011

How best to get your patients to stop smoking. Dr Alex Bobak GP and GPSI in Smoking Cessation Wandsworth, London

Smoking Cessation: Where Are We Now? Nancy Rigotti, MD

Tobacco Cessation The Role of the Dentist/Oral Medicinist

Clearing the Air: What You Need to Know and Do to Prepare to Quit Smoking

Month/Year of Review: March 2014 Date of Last Review: April 2012

AIDS for CESSATION PHARMACOTHERAPY. METHODS for QUITTING. NONPHARMACOLOGIC METHODS (cont d) NONPHARMACOLOGIC METHODS

I always try to understand why it is so tough to give up tobacco habits or specially smoking.

Cessation of Smoking By Nicotine Replacement Therapy

Pharmacological interventions for smoking cessation: an overview and network meta-analysis (Review)

Varenicline and Other Pharmacotherapies for Tobacco Dependence

Kicking the Habit Pharmacological Help for Smokers

Nicotine Replacement Therapy (NRT).

Chantix (Varenicline) and Risk of Cardiovascular Events

Addressing Tobacco Use in Iowa

Brief Intervention for Smoking Cessation. National Training Programme

Review Article. An overview of pharmacological aids available to enhance smoking cessation

3. Chantix [package insert]. New York, NY: Pfizer, Inc,; Ramon JM, Morchon S, Baena A, Masuet-Aumatell C. Combining varenicline and nicotine

Dispensing of Nicotine Replacement Therapy (NRT)

Objectives. Disclosure. Prevalence of Tobacco Use. Smoking Cessation Pharmacotherapy 3/2/2016.

Targeting Nicotine Addiction - The Possibility of a Healthier Future

TOBACCO CESSATION: INCORPORATING MOTIVATIONAL INTERVIEWING AND EXAMINING THE ROLE OF E-CIGS

Pharmacotherapy Safety and Efficacy in Adolescent Smoking Cessation

Pharmacotherapy for Tobacco Dependence Treatment

TOBACCO CESSATION: INCORPORATING MOTIVATIONAL INTERVIEWING AND EXAMINING THE ROLE OF E-CIGS

Tobacco Use & Dependence. Dr. Mohammad Taraz Clinical Pharmacist July 2012

Page 1. Pharmacologic Interventions for. Addictions. Objectives for This Talk. Outline for This Talk

SECTION 17: NICOTINE REPLACEMENT. Formulary and Prescribing Guidelines

Pharmacologic Interventions for. Addictions

Health Professional Manual

The 5A's are practice guidelines on tobacco use prevention and cessation treatment (4):

Drug Use Evaluation: Smoking Cessation

CENTRE FOR ADDICTION AND MENTAL HEALTH -MEDICAL DIRECTIVE ADMINISTRATION OF NICOTINE REPLACEMENT MEDICATIONS BY REGISTERED NURSES

Smoking Cessation and the Pharmacist

NCDs Risk Factor No. 3 - Smoking. Commonwealth Nurses Federation

Tobacco Cessation: Priority for Health Providers. Acknowledgements. Tobacco Cessation: Secondhand Smoke. Smoke-Free Environment & CA

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC)

UPDATE TREATMENT OF TOBACCO USE DISORDERS

Smoking Cessation Services Guidance

Formulary and Prescribing Guidelines

Effects of Smoking and Methods of Cessation By Chetan Kaher

Smoking. know the facts

YOUR GUIDE TO LIVING A SMOKE-FREE LIFE

Smoking It s never too late to quit

Varenicline Update. Serena Tonstad, MD, PhD Dept of Preventive Cardiology Ullevål University Hospital Oslo, Norway

Tobacco Cessation Toolkit

Tuberculosis and Tobacco

Pharmacological Treatments for Tobacco Users with Behavioral Health Conditions

Pharmacologic Therapy for Tobacco Use & Dependence Nicotine Replacement Therapy (NRT) and Bupropion

Rimonabant for treating tobacco dependence

Essentials of Smoking Cessation (2017)

The health risks of smoking

Ready to give up. Booklet 3

Medications to help you quit smoking

Cigarettes and Other Tobacco Products

Counseling the Tobacco Dependent Patient. Gretchen Whitby, CNP The Lung Center

If you have any concerns about taking this medicine, ask your doctor or pharmacist.

Save a Life in 3 Minutes

If treatment for tobacco addiction was evidence-based, what would it look like? Robert West University College London YORK, November 2005

Smoking Cessation Self-Management Plan and Care Plan

Transcription:

Time to Butt Out Adil Virani, BSc (Pharm), Pharm D, FCSHP

Objectives After this presentation, participants should be able to: 1. Describe the benefits of smoking cessation 2. List the withdrawal symptoms of quitting smoking 3. List the main treatment options to help people quit smoking and their likelihood of producing abstinence at 6-12 months 4. Describe the advantages and drawbacks of various pharmacological smoking cessation treatment options 5. List the appropriate dosages and duration of treatment of smoking cessation medications 6. Describe the monitoring parameters you would use when initiating a specific smoking cessation treatment

Agenda n Overview n Benefits of quitting smoking n Review of treatment options n Comparaison of efficacy and drawbacks of treatment options

Smoking Cessation The single most important step that smokers can take to enhance the length and quality of their lives. US Surgeon General, Guide to quitting smoking. American Cancer Society, 2006

Smoking Related Diseases n Cancer n Cervix n Pancreas n Kidneys n Stomach n Aortic aneurisms n Acute myeloid leukemia n Cataracts n Pneumonia n Nagging Spousitis n Gum disease n Lung cancer n Cardiovascular diseases n Emphysema n Sudden infant death syndrome n Low birth weight

Potential Lifetime Health Benefits of Quitting Smoking 1-2 Cardiovascular heart disease (CHD) risk is similar to never smokers Lung CA risk is 30-50% that of continuing Stroke risk returns to the level of people who have smokers never smoked at 5-15 years post-cessation Lung function starts to improve with cough, sinus congestion, fatigue and shortness of breath CHD risk is by 50% Cessation 3 months 1 year 5 years 10 years 15 years 1. CDC. Surgeon General Report 2004: American Cancer Society. Guide to Quitting Smoking. 2. US Department of Health & Human Services. The Health Benefits of Smoking Cessation: A Report of the Surgeon General. 1990.

Smoking Cessation Stopping smoking may have a greater effect on reducing the risk of mortality among patients with CHD who smoke than the effect of any other intervention or treatment. Critchley JA, Capewell S JAMA;2003;290:86-97 Smoking cessation is considerably more cost effective per life year saved than most pharmacological therapies (e.g., drugs for hypertension, hyperlipidemia). Benowitz NL Prog Cardiovasc Dis 2003;46:91-111

Did you know? n ~40% of smokers attempt quitting each year n Most attempts are unaided n 6 mo abstinence rates (unaided) = 3-5% n Most relapse in the first week n Most smokers have several triggers n Nicotine s half life is <2 hrs n Withdrawal symptoms peak at 1 week and can last months Nides, M. Am J Med 2008:121;S20-31

Nicotine Withdrawal Symptoms Symptom Duration Dizziness A few days Restlessness/anxiety A few days or weeks Cough, dry throat or mouth A few days or weeks Bad breath A few days or weeks Insomnia About one week Irritability, frustration, anger About 1-2 weeks Constipation, gas, bloating About 1-2 weeks Canadian Lung Association, 2001.

Nicotine Withdrawal Symptoms Symptom Duration Difficulty concentrating/ feeling sleepy A few weeks Headaches Can occur during the first few weeks Increased appetite Can last several weeks Fatigue, trouble getting up in the morning Two to four weeks Boredom, loneliness Variable Craving for tobacco Can last several months Canadian Lung Association, 2001.

If you had a patient (with your age and medical history) who smoked 1ppd x 4 yrs what method would you use to quit?

Going smoke free n Ask, Assess and Assist n Nonpharmacological approaches n Nicotine Replacement Therapy (NRT) n The patch n Chewing gum, lozenges n Nasal spray n Nicotine Inhaler n Delayed onset options n Bupropion (antidepressant) n Varenicline (nachr partial agonist/antagonist) n Nortriptyline (antidepressant) 2 nd line [OR = 2.14 (1.49-3.06)] n Clonidine (antihypertensive) 2 nd line [OR = 1.89 (1.30-2.74)]

Ask, Assess and Assist YES: NO: Ask: Are you willing to try quitting? S...Set a quit date T...Tell family & friends A...Anticipate challenges R...Remove tobacco items T Tobacco replacements? Here to help if you change your mind. Assess Conviction: 1 to 10 Assess Confidence: 1 to 10

Need a Comprehensive Strategy n Smoking addiction has two main components: n Psychological (behavioural factors) n Physiological (pharmacological treatment) n Advice and behavioural support increase the chances of successfully quitting! n The biggest predictor of success is the number of quit attempts. Jarvis MJ. BMJ 2004;328:277-279. Hughes JR. CA Cancer J Clin 2000;50:143-151.

Nicotine Replacement Therapy (NRT) n Delivers nicotine that binds to the nicotinic acetylcholine receptor (nachr) receptors 1 n Does not counter the additional satisfaction from smoking 1 n NRTs does not deliver nicotine to the circulation as fast as smoking 2 1. American Heart Association website. 2. Sweeney CT et al. CNS Drugs 2001;15:453-467.

Nicotine Plasma Levels by Cigarettes vs. NRT Products Sweeney CT et al. CNS Drugs 2001;15:453-467.

NRT: Nicotine Gum n Nicotine polacrilex n (e.g., Nicorette, Thrive gum ) n Method of delivery: n Nicotine released from gum upon chewing n Bite the gum then, chew, chew until tingle, then park for 30-60 sec, repeat for 30 min n Start with about 10-12 pieces/day n Chew regularly for 4-12 wks, then PRN cravings for up to 6 months n Avoid acidic beverages (coffee, alcohol, pop, citrus fruit juice) within 15 min ( absorption)

NRT: Nicotine Lozenge n Dehydrated Nicotine bitartrate n e.g.,thrive Lozenge n Nicotine released by sucking on lozenge..then park lozenge (when taste is strong); repeat x 30 min n Dosage: n > 20 cigarettes / day = 2mg n < 20 cigarettes / day = 1 mg n 5-15 lozenges/ day for 1-3 months, then PRN cravings

Nicotine Gum or Lozenge: Common Adverse Events Local Jaw pain, tooth disorders Gum sticking to dentures Throat irritation (5%) Stomatitis (4%) Gingivitis (1%) Taste perversion GI Hiccups (10%) Dyspepsia (9%) Nausea (9%) CNS symptoms Headache (11%) Dizziness (4%) Insomnia (2%)

Nicotine Inhaler n Nicotine is absorbed through oral mucosa n Dose: n 1 cartridge (4mg) n 4-12 cartridges/d X 3 mo, then taper n 20 min/cartridge n Expires within 24 hours if not used n Side effects n Cough n Mouth and throat irritation n Changing the technique might help in these cases (small puffs less irritating than long puffs) n Rhinitis, pharyngitis

NRT: Nicotine Patches n E.g., Habitrol, Nicoderm n New patch (7, 14, 21 mg) applied every 24 hrs, taper dose q 3-4 wks n 3 months therapy n Advantages: n Eliminate variability of GI absorption n Reduce nicotine first-pass metabolism n Enhance patient compliance n Disadvantages: n Local skin irritation n Insomnia n Wears off in 20-24 hrs

Efficacy of NRT vs. Placebo (@ 6 or longer) Comparison Trials (n) Participants (n) Pooled OR (95% CI) Gum 52 17,783 1.66 (1.52 1.81) Patch 37 16,691 1.81 (1.63 2.02) Nasal spray 4 887 2.35 (1.63 3.38) Inhaler 4 976 2.14 (1.44 3.18) Tablets/lozenges 4 2739 2.05 (1.62 2.59) Combination vs. single type 7 3202 1.42 (1.14 1.76) Any NRT vs. control 103 39,503 1.77 (1.66 1.88) 1. Silagy C et al. Cochrane Database Syst Rev 2004;(3):CD000146. 2. Stead L, Lancaster T. Int J Epidemiol 2005;34:1001 1003.

Is it withdrawal or too much NRT? Symptoms Withdrawal Overdose Anxiety, irritability Insomnia Headache, dizziness Nausea, vomiting, abdominal pain, diarrhea Salivation Sweating, flushing Palpitations

NRT Contraindications n Unstable cardiac condition n 2 weeks following heart attack n Unstable angina n Any unstable cardiac condition n Pregnancy and breastfeeding??? n Patients under 18 years old???

Safety of NRT n NRT delivers nicotine without the toxins associated with smoking 1 n Toxins, not nicotine, cause most tobacco-related health concerns 1 n Tobacco smoke contains >4000 chemicals; at least 50 are carcinogenic 2 n In more than 100 clinical trials, including longterm (>5-yr) data, 3 NRT has not been associated with increased risk of cancer 1 1. Benowitz NL. In: Benowitz NL (ed.). Nicotine safety and toxicity. Oxford University Press, 1998; pp.185-95. 2. Health Canada. The facts about tobacco.http://www.hc-sc.gc.ca/hecs-sesc/tobacco/facts/index.html. 3. Murray RP, et al: Chest 1996; 109(2):438-45.

NRT: Key Messages n Safe and effective for smoking cessation (esp. in conjunction with a behavioural program). n Delivers nicotine (more slowly and at lower levels vs. smoking) to nachr receptors n NNT vs placebo ~11-19 n Acidic beverages affect absorption n NO Carbon monoxide, oxidants or >4000 other chemicals and mutagens! n The use of NRT is not associated with any increase in risk of MI, stroke, cancer or death. Hubbard R et al. Tobacco Control 2005;14:416-21 Benowitz NL. Nicotine safety and toxicity. Oxford University Press, 1998; pp.185-95.

Which of the following statements regarding bupropion is/are TRUE? A. Bupropion s efficacy at 6 months is equivalent or slightly better than NRT B. Bupropion s efficacy at 6 months is less effective than NRT C. Bupropion s efficacy at 6 months is superior to nortriptyline D. Bupropion s efficacy at 6 months is equivalent to varenicline

Bupropion SR (Zyban, Wellbutrhin ) n Non-nicotine SR tablet n Blocks reuptake of dopamine and noradrenaline 1,2 n Non-competitive inhibition of brain nicotine receptors n Started 1-2 wks before quit date n 150mg once daily x 3 days, then bid for 7-12 wks n Contraindications n History of head injury, CNS tumour, seizures n Anorexia, bulimia, heavy alcohol use 1. Henningfield JE et al. CA Cancer J Clin 2005;55:281 299. 2. Foulds J et al. Expert Opin Emerg Drugs 2004;9:39 53.

Most Frequent Adverse Events With Bupropion Insomnia 20-40% Dry mouth 10% Disturbed concentration 9% Dizziness 9% Nausea 9% Constipation 8% Discontinuations 8%

n Tricyclic antidepressant Nortriptyline n Blocks the reuptake of NA and 5HT n Start 1-3 wks before quit date n 25mg daily and titrate up to 100 mg n Treat for 12 wks n As effective as buproprion n Side effects: n Dry mouth, blurred vision, constipation, sedation, confusion, urinary retention

Bupropion & Nortriptyline: Key Messages n >30 RCTs for Bupropion (n>7,000) n Abstinence rates at 12 months: n BUP 19% vs 9% Placebo n Pooled OR ~ 2 n Nortriptyline (75-100mg) as effective as BUP n NNT (for both agents) ~ 10-12 Hughes JR et al. The Cochrane Library, 2004, Issue 3, Art. NO CD 000031. NICE Guidance on the use of NRT and bupropion for smoking cessation. No. 39. March 2002. Eisenberg MJ et al. CMAJ. July 2008;179(2):135-144

Varenicline (Champix ) n Partial agonist and antagonist at (α4β2) nachr n Health Canada NoC: January 24, 2007 n Start before quit date n 0.5mg 1mg bid x 12 weeks n Though not studied, given the mode of action, there may be limited additional benefit of combo with NRT n May be more effective than NRT or bupropion? Cahill et al, Cochrane Database of Systematic Reviews, 2007 Gonzales D et al. JAMA 2006;296:47-55. Jorenby DE et al. JAMA 2006;296:56-63.

α4β2 nachr Partial Agonists Smoking No Partial Ag No Smoking Partial Ag Smoking + Partial Ag Nicotine α4β2 nachr Nicotine Part Ag Part ag Agonist Partial Agonist Antagonist Response 100% 50% Potential to relieve craving and withdrawal when quitting 50% Potential to block reinforcing effects when smoking Dual action of a partial agonist

Eisenberg MJ et al. CMAJ. July 2008;179(2):135-144 n Extensive Meta-analysis of RCTs n 69 trials; n=32,908 pts n Included studies reporting 6-12 mo abstinence rates for 7 pharmacolgical therapies n Objectives: n Summarize the efficacy of approved therapies n Compare varenicline vs. bupropion n Indirect comparison of all 7 approved therapies

Nicotine Gum/Patch Efficacy With Nicotine Gum or Patch, the odds of abstinence at 6 months or longer is 1.71 or 1.95

Bupropion Efficacy Bupropion doubles your odds of abstinence at 6 months or longer

Varenicline Efficacy Varenicline more than doubles your odds of abstinence at 6 months or longer

Varenicline vs. Bupropion at 26 wks + Bupropion Though quite rates are small, Varenicline increases the odds of abstinence at 6 months over bupropion Cahill et al, 2007

Varenicline vs. Bupropion at 52 wks Varenicline (N=823)(%) Bupropion (N=799) (%) Absolute Benefit (%) NNT 21.1 13.9 7.2 14 Cahill et al, 2007

Efficacy of treatments Nicotine gum Nicotine patch Nicotine inhaler Bupropion Varenicline Treatment Duration (months) 1-3 2-3 3-6 (longer) 2-3 3 Dosage 2, 4 mg 7, 14, 21mg 6-12 cartridges / day (higher) 150-300 mg/day 0.5-1 mg bid Efficacy at 6-12 month vs Placebo (OR [CI]) Abstinence rates at 6 mo (or longer) +/-3%; Placebo =8% NNTs (vs. Placebo) for abstinence at 6 mo or longer). 1.66 [1.65] (1.52-1.81) 1.81 [1.88] (1.63-2.02) 2.14 [2.18] (1.44-3.18) 2.06 [2.12] (1.77-2.40) [2.55] (1.99-3.24) 13% 14.5% 17% 16.5% 26% 19 16 11 12 6-8 Hughes JR et al. Cochrane Database Syst Rev 2004; Cahill C et al. Cochrane Database Syst Rev 2007;

Eisenberg MJ et al. CMAJ. July 2008;179(2):135-144

Adverse Effects Nicotine gum/ Lozange Nicotine patch Nicotine inhaler Bupropion Varenicline Common side effects Dyspepsia (9%) Nausea (9%) Hiccups (10%) Headache (11%) Jaw pain Denture issues Throat irritation (5%) Headache Disturbed sleep Site rash Throat irritation Sneezing Coughing Rhinitis Pharyngitis Insomnia (20%) Dry mouth Disturbed concentration Nausea Nausea (30%) Headaches Abnormal dreams Constipation Serious side effects Seizures Angioedema Suicidal ideation Severe allergic reactions Cost/ 3month $250-400 $280-345 500 (6x/d) $180 (Nortriptyline = $75) $330 http://hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2010/champix_2_hpc-cps-eng.php Hughes JR et al. Cochrane Database Syst Rev 2004; Cahill C et al. Cochrane Database Syst Rev 2007

Limitations of Current data n Many patients lost to follow up (high drop out rates (30-45%) at 52 wks n No head-to-head trials of varenicline vs. NRT n Limited data for some treatment options n Need to look at a similar time frame n Abstinence data >12 months is sparse n Patient characteristics differ n Publication bias? n No negative studies published n 2 studies dominate varenicline data (published multiple times?)

Questions?